Business Wire

MA-EVERBRIDGE

23.9.2020 15:31:17 CEST | Business Wire | Press release

Share
Former World Head of State to Address Attendees at Everbridge’s COVID-19: Road to Recovery (R2R) Symposium, Joining Dr. Anthony Fauci, Sir Richard Branson, and Dr. Sanjay Gupta as Keynotes, October 14-15, 2020

Everbridge , Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM ), today announced that a former World Head of State will address attendees to its Autumn 2020 “COVID-19 R2R: The Road to Recovery” virtual leadership summit to be held October 14-15, 2020, covering the path forward amid the COVID-19 pandemic. The addition of a former World Head of State represents the latest in a top-tier line-up of leading experts and C-level executives who will share their perspectives on best practices for the safe reintegration of people back to work, campuses and public spaces; the restoration of revenue-generating operations; and the protection of citizens on a countrywide scale amid the coronavirus pandemic. Keynote speakers include presidential advisor and Director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH) Dr. Anthony Fauci , Virgin Group Founder Sir Richard Branson , and renowned neurosurgeon and CNN Chief Medical Correspondent Dr. Sanjay Gupta .

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200923005554/en/

To attend the “COVID-19 R2R: The Road to Recovery” virtual leadership summit, please visit Everbridge’s event registration page .

“The addition of a former World Head of State reinforces the international magnitude of the topics to be addressed at our COVID-19 ‘Road to Recovery’ symposium,” said Everbridge Chief Executive Officer David Meredith. “C-level executives and other global leaders will provide an update on the world’s COVID-19 response and offer actionable advice for mitigating the impact of the pandemic as we reopen our offices, schools and economies.”

The first day of the event, October 14th , will include keynotes from Dr. Sanjay Gupta and a former World Head of State . Day two, October 15th , will feature keynotes from Sir Richard Branson and Dr. Anthony Fauci .

The symposium will focus on the policies and actions organizations can take during the pandemic to keep people safe, execute contact tracing, return people to workplaces, campuses, and public spaces, protect supply chains, restore operations, and help organizations manage their reputations and communications to foster consumer safety and trust; all while managing across multiple critical events that could include hurricanes, wildfires, production stoppages, IT outages and cyberattacks.

To see a current list of speakers and register for the event, please visit here . Representative C-level speakers from Fortune 500 and international corporations include a Fortune 25 Chief Executive Officer (CEO), Fortinet Founder, Chairman of the Board, and CEO Ken Xie, Accenture’s Arlin Pedrick, Auburn University’s President Jay Gogue, Aviva’s John Bernard, Capital One’s William Baker, Fannie Mae’s Christopher Porter, Humana’s Stephan Pazienza, Lumen Technologies’ (formerly CenturyLink) Executive Vice President of Human Resources Scott Trezise, Optum’s Allison Miller, Rackspace Technology’s Chief People and Legal Officer Holly Windham, and Siemens ’ Marco Mille, among others.

Speakers representing the healthcare and government sectors include Roberta Levy Schwartz, Ph.D., FACHE, Chief Executive Officer, Executive Vice President and Chief Innovation Officer at Houston Methodist Hospital ; Dr. Judy Monroe, Chief Executive Officer of the CDC Foundation ; Dr. Nancy Messonnier, Director of the Center for the National Center for Immunization and Respiratory Diseases (NCIRD ); Matt Roman, Chief Digital Officer of Duke University Health System ; Curt Wood, Chief Information Officer of the Commonwealth of Massachusetts ; Rebecca Baudendistel, Director of Public Warning at New York City Emergency Management Department ; Víðir Reynisson, Chief Superintendent of the Office of National Commission of Police in Iceland ; Benoît Vivier, European Union institutions liaison at the European Emergency Number Association (EENA) ; and Michael Hallowes, former National Director of Australia’s Emergency Alert program and Managing Director of Zefonar .

Over 5,300 global organizations use Everbridge’s CEM Platform to assess threats, monitor the wellbeing of their workforce, rapidly communicate warnings, and protect supply chains. At the onset of the pandemic, Everbridge rapidly launched its COVID-19 Shield™ Return to Work and Contact Tracing software solutions followed by the introduction of Everbridge Control Center , the industry’s first off-the-shelf physical security information management software platform to help organizations return to work while complying with social distancing and Personal Protective Equipment (PPE) policies. Since the pandemic began, Everbridge customers have used its software to send more than 780 million coronavirus-related communications with vital information and instructions to safeguard their populations, employees, patients, and students.

Everbridge serves over 3,700 first responder agencies and 1,500 healthcare entities including the top pharmaceutical, biomedical and medical device and manufacturing companies, as well as the largest healthcare systems (overseeing more than 25 percent of all hospital beds in the U.S.), managed care organizations, pharmacies, and statewide health alert networks (HANs), including the CDC and the NIH.

The Everbridge Platform reaches over 600 million people and currently supports the countrywide public warning system deployments in all major regions of the world . Everbridge supports population-wide alerting in 11 countries across Europe, Asia, Oceania, The Middle East, Africa, and South America including Australia , Iceland , the Netherlands, New Zealand, Norway , Peru , Singapore and Sweden . Everbridge’s population alerting capabilities also power the entire states of California , Massachusetts , Vermont , New York , Connecticut , and Florida , as well as municipalities, counties and cities within 49 of the 50 United States, within all of Canada’s provinces, and throughout Europe and Asia, including deployments within multiple populous states in India .

About Everbridge

Everbridge, Inc. (NASDAQ: EVBG) is a global software company that provides enterprise software applications that automate and accelerate organizations’ operational response to critical events in order Keep People Safe and Businesses Running™. During public safety threats such as active shooter situations, terrorist attacks or severe weather conditions, as well as critical business events including IT outages, cyber-attacks or other incidents such as product recalls or supply-chain interruptions, over 5,300 global customers rely on the Company’s Critical Event Management Platform to quickly and reliably aggregate and assess threat data, locate people at risk and responders able to assist, automate the execution of pre-defined communications processes through the secure delivery to over 100 different communication devices, and track progress on executing response plans. Everbridge serves 8 of the 10 largest U.S. cities, 9 of the 10 largest U.S.-based investment banks, 47 of the 50 busiest North American airports, 9 of the 10 largest global consulting firms, 8 of the 10 largest global automakers, 9 of the 10 largest U.S.-based health care providers, and 7 of the 10 largest technology companies in the world. Everbridge is based in Boston with additional offices in 14 cities around the globe. For more information visit www.everbridge.com

Cautionary Language Concerning Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including but not limited to, statements regarding the anticipated opportunity and trends for growth in our critical communications and enterprise safety applications and our overall business, our market opportunity, our expectations regarding sales of our products, our goal to maintain market leadership and extend the markets in which we compete for customers, and anticipated impact on financial results. These forward-looking statements are made as of the date of this press release and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. Words such as “expect,” “anticipate,” “should,” “believe,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “could,” “intend,” variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond our control. Our actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to: the ability of our products and services to perform as intended and meet our customers’ expectations; our ability to successfully integrate businesses and assets that we may acquire; our ability to attract new customers and retain and increase sales to existing customers; our ability to increase sales of our Mass Notification application and/or ability to increase sales of our other applications; developments in the market for targeted and contextually relevant critical communications or the associated regulatory environment; our estimates of market opportunity and forecasts of market growth may prove to be inaccurate; we have not been profitable on a consistent basis historically and may not achieve or maintain profitability in the future; the lengthy and unpredictable sales cycles for new customers; nature of our business exposes us to inherent liability risks; our ability to attract, integrate and retain qualified personnel; our ability to maintain successful relationships with our channel partners and technology partners; our ability to manage our growth effectively; our ability to respond to competitive pressures; potential liability related to privacy and security of personally identifiable information; our ability to protect our intellectual property rights, and the other risks detailed in our risk factors discussed in filings with the U.S. Securities and Exchange Commission (“SEC”), including but not limited to our Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 28, 2020. The forward-looking statements included in this press release represent our views as of the date of this press release. We undertake no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

All Everbridge products are trademarks of Everbridge, Inc. in the USA and other countries. All other product or company names mentioned are the property of their respective owners.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release

As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release

Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release

Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 15:00:00 CEST | Press release

Appointment Reflects Firm's Vision for the Future of Legal Practice Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye